Ann: Reinstatement to Official Quotation, page-10

but more rationally and financially sound consideration
should place this stock around $300- $500 mill after phase one into phase three based on past peer pricing across the board
references acw relative value presentations and just recently imu presentation of similar bio pricing of companies at various stages of fda progress and deals
not my analysis just facts of price deals
so blue sky here for those that believe that rec will progess fda trials/ examinations easily
all the pre clinical trials and tests suggest so
and thats before the wild card of covid efficacy as a treatment option in added on
also now uti infections therapy, likely solution to gonorrhea resistance issues to penicillin, and topical treatment of burns more efficaciously

what a multiple playground
dyi - look up my references here - not pumping and dumping - just pointing you guys to the horizon
im more excited now sure
every month its just expanding in possibilities